Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Triage and Treatment of Atypical Glandular Cells (AGC) Detected in Screening
Sponsor: Karolinska Institutet
Summary
The risk of cervical cancer after diagnosis with atypical glandular cells (AGC) detected by screening is elevated for 15 years after discovery. The current recommendation is that when AGC is detected during screening, referel is made to a gynecologist for colposcopy with biopsy within 3 months after the index test. Repeated tests should be done after one year and after two years and if these are negative, the woman can return to routine screening. Given the increased risk of cancer associated with AGC a new evaluation of the optimal follow-up and treatment of AGC, which is detected during screening, is carried out. In this randomized study, women with AGC will be randomized to routine treatment according to current guidelines or to conization. The aim of the study is to determine which of the two treatments is most effective.
Official title: Clinical Triage and Treatment of Atypical Glandular Cells (AGC) Detected in Screening: Randomized Healthservices Trial
Key Details
Gender
FEMALE
Age Range
23 Years - 64 Years
Study Type
INTERVENTIONAL
Enrollment
280
Start Date
2022-01-27
Completion Date
2029-12
Last Updated
2025-03-19
Healthy Volunteers
No
Conditions
Interventions
Conization
A cone biopsy to remove abnormal tissue.
Colposcopy
1. Colposcopy with biopsy within 3 months,endocervical sample, ultrasound and endometrial biopsy if the woman is ≥40 2. Colposcopy after 12 months if the first colposcopy and biopsies are normal 3. Cytology and HPV testing at 12 and 24 months if the second colposcopy is normal
Locations (1)
Karolinska University Hospital
Stockholm, Sweden